JOURNAL ARTICLE

Dupilumab demonstrates greater improvement in disease activity than standard-of-care H1-antihistamines in CSU.

  • Published In: British Journal of Dermatology, 2024, v. 190. P. ii12 1 of 3

  • Database: Academic Search Ultimate 2 of 3

  • Authored By: Beck, Lisa A.; Casale, Thomas B.; Mortensen, Eric; Laws, Elizabeth; Thomas, Ryan B.; Chien-Chia Chuang 3 of 3

Abstract

This article focuses on the efficacy of dupilumab, an add-on treatment, compared to standard-of-care (SOC) H1-antihistamines in patients with chronic spontaneous urticaria (CSU) who remain symptomatic. In the randomized, placebo-controlled LIBERTY-CSU CUPID Study A, dupilumab combined with SOC showed greater improvements in Urticaria Activity Score over 7 days (UAS7), Itch Severity Score over 7 days (ISS7), and Hives Severity Score over 7 days (HSS7) at 24 weeks than placebo with SOC, with notably higher proportions of patients achieving minimal important difference thresholds. The safety profile of dupilumab was consistent with previous findings. The study was sponsored by Sanofi and Regeneron Pharmaceuticals Inc. and registered under ClinicalTrials.gov Identifier NCT04180488.

Additional Information

  • Source:British Journal of Dermatology. 2024/02, Vol. 190, pii12
  • Document Type:Article
  • Subject Area:Complementary and Alternative Medicine
  • Publication Date:2024
  • ISSN:0007-0963
  • DOI:10.1093/bjd/ljad498.015
  • Accession Number:175380298
  • Copyright Statement:Copyright of British Journal of Dermatology is the property of Oxford University Press / USA and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Looking to go deeper into this topic? Look for more articles on EBSCOhost.